Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1995
Business Overview: Bio-Rad operates in three primary segments: Life Science, Analytical Instruments, and Clinical Diagnostics. The company manufactures and sells laboratory products, genetic imaging products, and semiconductor instruments globally, with primary manufacturing in the United States.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 1995 | 9 Months Ended Sep 30, 1995 |
|---|---|---|
| Net Sales | $92,905 | $288,684 |
| Gross Profit | $52,937 | $165,496 |
| Gross Margin | 57.0% | 57.3% |
| Income from Operations | $6,649 | $28,445 |
| Net Income | $4,440 | $19,006 |
| Earnings Per Share | $0.55 | $2.34 |
| Cash and Cash Equivalents | $7,564 | $7,564 (Balance Sheet) |
| Net Cash from Operating Activities | N/A | $23,344 |
| Total Debt (Current + Long-term) | $39,965 | $39,965 (Balance Sheet) |
Material Changes vs. Prior Period
- Sales Growth: Net sales increased 11% for the quarter and 12% for the nine-month period compared to 1994. Growth was driven by the Life Science and Analytical Instruments segments. A weakened U.S. dollar contributed approximately $3.3 million to quarterly sales and $13.0 million to year-to-date sales.
- Profitability: Net income rose 14% for the quarter and 67% for the nine-month period. Operating income decreased slightly for the quarter ($6.6M vs $7.3M) due to restructuring costs but increased for the nine-month period ($28.4M vs $27.6M).
- Restructuring Costs: The company incurred $1.5 million in restructuring costs in the third quarter of 1995 related to closing a New York sales office and warehouse in the Life Science segment. No such costs were recorded in the prior year periods.
- Interest Expense: Interest expense decreased significantly due to a 30% reduction in average borrowings for the quarter and a 33% reduction for the nine-month period.
- Tax Rate: The effective tax rate was 25% for both the quarter and nine-month period, down from 35% in the prior year, due to the utilization of foreign loss carryforwards and tax credits.
Guidance, Outlook, and Risks
- Outlook: Management expects tax benefits from foreign loss carryforwards and foreign sales corporation benefits to continue into 1996. The company plans to continue expanding R&D spending to support long-term growth.
- Acquisitions: In July 1995, Bio-Rad acquired an infrared spectrometer product line to complement its Analytical Instruments segment. The company may consider additional acquisition opportunities.
- Liquidity: The company reported $7.6 million in cash and cash equivalents and $55.3 million available under its revolving credit agreement. Management states available funds are adequate for operations and R&D.
- Risks and Contingencies:
- Inventory: Inventories increased by $10.6 million year-to-date, partly due to production increases for Life Science instrumentation and new Clinical Diagnostics products.
- Receivables: Accounts receivable increased by $4.2 million, influenced by the weakened dollar, slower payments due to Italian healthcare reimbursement reorganization, and sales of complex systems with longer collection times.
- Legal: The EPA notified the company in March 1995 that it does not intend to pursue Bio-Rad as a potentially responsible party for a site in Louisiana.
Investor Verification Checklist
- Verify the sustainability of the 25% effective tax rate and the availability of foreign tax loss carryforwards.
- Monitor inventory levels and turnover, given the $10.6 million increase and potential capital growth requirements.
- Assess the impact of the weakened U.S. dollar on future gross margins and sales growth.
- Track the collection of accounts receivable, particularly regarding the Italian healthcare reimbursement delays.
- Confirm the realization of the estimated $1.0 million annual savings from the New York facility closure.